NSI-566, our lead cell therapy candidate, is a spinal-cord derived neural stem cell line. NSI-566 is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS), ischemic stroke and AIS-A complete chronic spinal cord injury (cSCI).
NSI-189 is the lead compound in our neurogenic small molecule drug discovery program. NSI-189 is being evaluated for the treatment of cognition in major depressive disorder (MDD). Data suggest that NSI-189 works by promoting synaptogenesis or neurogenesis in the hippocampus; a different mechanism of action than currently marketed antidepressants. Top-line results from an exploratory Phase 2 clinical trial were announced in July 2017
